Caine V A, Foulds G, Handsfield H H
Antimicrob Agents Chemother. 1984 Nov;26(5):683-5. doi: 10.1128/AAC.26.5.683.
The efficacy of intramuscular sulbactam for uncomplicated gonorrhea was assessed in 20 men infected with beta-lactamase-negative Neisseria gonorrhoeae. Ten subjects received 2.0 g of sulbactam given in a single intramuscular dose with 1.0 g of probenecid orally; 4 of 10 urethral infections persisted, as did one rectal infection. Ten subjects were treated with 0.5 g of intramuscular sulbactam given twice, 4 h apart; 3 of 10 urethral infections and 2 of 2 rectal infections persisted. The geometric mean MIC of sulbactam for 20 pretreatment isolates of N. gonorrhoeae was 1.37 microgram/ml (range, 0.25 to 8.0 micrograms/ml). Serum levels of sulbactam, determined for nine subjects in the two treatment groups, fell below the MIC of some gonococci after less than 6 h with both regimens. In the regimens studied, sulbactam alone is not suitable as therapy for uncomplicated gonorrhea. determined for nine subjects in the two treatment groups, fell below the MIC of some gonococci after less than 6 h with both regimens. In the regimens studied, sulbactam alone is not suitable as therapy for uncomplicated gonorrhea.
对20例感染β-内酰胺酶阴性淋病奈瑟菌的男性患者评估了肌内注射舒巴坦治疗单纯性淋病的疗效。10名受试者单次肌内注射2.0g舒巴坦,并口服1.0g丙磺舒;10例尿道感染中有4例持续存在,1例直肠感染也持续存在。10名受试者接受0.5g肌内注射舒巴坦,间隔4小时给药两次;10例尿道感染中有3例以及2例直肠感染中的2例持续存在。20株淋病奈瑟菌治疗前分离株对舒巴坦的几何平均MIC为1.37μg/ml(范围为0.25至8.0μg/ml)。在两个治疗组中对9名受试者测定的舒巴坦血清水平,两种给药方案在不到6小时后均降至某些淋球菌的MIC以下。在所研究的给药方案中,单用舒巴坦不适合作为单纯性淋病的治疗方法。在两个治疗组中对9名受试者测定的舒巴坦血清水平,两种给药方案在不到6小时后均降至某些淋球菌的MIC以下。在所研究的给药方案中,单用舒巴坦不适合作为单纯性淋病的治疗方法。